I've followed Entelos for a number of years, and they've made great strides this year. Earlier this year, they in licensed a series of Phase I candidates from J&J. Now their acquisition of Iconix is quite interesting. Given Entelos' historical focus on efficacy, their acquisition of a tox-oriented company sounds like a great fit.
Entelos Acquires Iconix Biosciences
"We believe the combination of our predictive efficacy models with Iconix's toxicology expertise can create a new paradigm for discovering and developing drugs," commented James Karis, President and CEO of Entelos, Inc. "Drug failures are often due to efficacy or toxicity issues, and while Entelos' predictive disease models address efficacy, Iconix's toxicology databases help to address toxicities. In addition, Entelos' recently announced collaboration with the FDA to build a model of drug-induced human liver injury to identify patients at risk for developing hepatotoxicity and the addition of Iconix will expand our capability for drug safety assessment."
Recent Comments